Literature DB >> 32329440

PCSK9 promotes the secretion of pro-inflammatory cytokines by macrophages to aggravate H/R-induced cardiomyocyte injury via activating NF-κB signalling.

Cheng-Long Yang1, Yi-Di Zeng, Zhi-Xi Hu, Hao Liang.   

Abstract

The upregulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) was reported to be involved in regulating the levels of inflammatory markers and apoptosis in macrophages. This study aims to investigate the function and regulation of PCSK9 in myocardial ischaemia. The results of our study showed dramatically increased expression of PCSK9 induced by hypoxia/reoxygenation (H/R) stress rather than by apoptosis in primary murine cardiomyocytes and HL-1 cells. Moreover, PCSK9 promoted H/R-induced pro-inflammatory cytokine release from macrophages, while silencing of PCSK9 inhibited the expression of the pro-inflammatory cytokines TNF-α, IL-6 and IL-1β. Additionally, PCSK9 facilitated the release of pro-inflammatory cytokines from macrophages under H/R conditions, which decreased cardiomyocyte viability and promoted apoptosis of cardiomyocytes. For the underlying mechanisms, we identified PCSK9-induced NF-κB activation as being involved in the cardiomyocyte apoptosis, which was blocked by the NF-κB inhibitor BAY 11-7082. Collectively, this study provides new insights into the therapeutic possibility of regulating PCSK9 in cardiomyocytes for the treatment of ischaemic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32329440     DOI: 10.4149/gpb-2019057

Source DB:  PubMed          Journal:  Gen Physiol Biophys        ISSN: 0231-5882            Impact factor:   1.512


  5 in total

Review 1.  PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation.

Authors:  Ioanna Andreadou; Maria Tsoumani; Gemma Vilahur; Ignatios Ikonomidis; Lina Badimon; Zoltán V Varga; Péter Ferdinandy; Rainer Schulz
Journal:  Front Physiol       Date:  2020-11-12       Impact factor: 4.566

2.  IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study.

Authors:  Jacek Kubica; Przemysław Podhajski; Przemysław Magielski; Aldona Kubica; Piotr Adamski; Roman Junik; Jarosław Pinkas; Eliano P Navarese
Journal:  Cardiol J       Date:  2021-11-17       Impact factor: 2.737

3.  PCSK9 Imperceptibly Affects Chemokine Receptor Expression In Vitro and In Vivo.

Authors:  Sai Sahana Sundararaman; Linsey J F Peters; Sumra Nazir; Andrea Bonnin Marquez; Janneke E Bouma; Soyolmaa Bayasgalan; Yvonne Döring; Emiel P C van der Vorst
Journal:  Int J Mol Sci       Date:  2021-12-01       Impact factor: 5.923

Review 4.  PCSK9 Inhibition: From Current Advances to Evolving Future.

Authors:  Chunping Liu; Jing Chen; Huiqi Chen; Tong Zhang; Dongyue He; Qiyuan Luo; Jiaxin Chi; Zebin Hong; Yizhong Liao; Shihui Zhang; Qizhe Wu; Huan Cen; Guangzhong Chen; Jinxin Li; Lei Wang
Journal:  Cells       Date:  2022-09-23       Impact factor: 7.666

Review 5.  Insight into the Evolving Role of PCSK9.

Authors:  Mateusz Maligłówka; Michał Kosowski; Marcin Hachuła; Marcin Cyrnek; Łukasz Bułdak; Marcin Basiak; Aleksandra Bołdys; Grzegorz Machnik; Rafał Jakub Bułdak; Bogusław Okopień
Journal:  Metabolites       Date:  2022-03-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.